Securities code: 002932 securities abbreviation: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) Announcement No.: 2022-007 Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Announcement on the completion of the share reduction plan of the company’s directors
The shareholder Mr. Wang Jianfei guarantees that the information provided to the company is true, accurate and complete without false records, misleading statements or major omissions.
The company and all members of the board of directors guarantee that the contents of the announcement are consistent with the information provided by the information disclosure obligor.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) (hereinafter referred to as “the company”) disclosed the pre disclosure announcement on the share reduction plan of the company’s directors (Announcement No. 2022-003) on January 15, 2022. Mr. Wang Jianfei, the director of the company, plans to reduce part of the company’s shares held by him in the form of centralized bidding within six months after 15 trading days from the date of the pre disclosure announcement, The number of shares to be reduced shall not exceed 7875 (accounting for 0.0075% of the total share capital of the company). For details, see http://www.cn.info.com.cn. On February 16, 2022, the company received the notification letter of the completion of the implementation of the share reduction plan from Mr. Wang Jianfei, the director of the company. On February 16, 2022, Mr. Wang Jianfei reduced 7875 shares of the company (accounting for 0.0075% of the total share capital of the company) by means of centralized bidding transaction. The reduction of Mr. Wang Jianfei is as follows:
1、 Shareholder reduction
1. Share reduction by shareholders
Proportion of the number of shares reduced by shareholders in the price range of reduction in the total share capital of the company during the period of reduction (yuan / share) (share)
Wang Jianfei centralized bidding 2022 / 2 / 16 76.40-76.57 7875 0.0075%
Note: the shares reduced by Mr. Wang Jianfei come from the shares issued before the initial public offering.
2. Shareholding of shareholders before and after this reduction
Name of shareholders: shares held before the reduction; shares held after the reduction; shares of stock nature; proportion of shares in total share capital; proportion of shares in total share capital (shares) (%) (shares) (%)
Total shares held 31500 0.0300 23625 0.0225
Wang Jianfei, including: unlimited sales bar 7875 0.0075 —
Piece shares
Shares with limited sales conditions 23625 0.0225 23625 0.0225
2、 Main contents of this reduction plan
1. Mr. Wang Jianfei, the director of the company, has made a pre disclosure of the share reduction in accordance with relevant regulations. The above reduction is consistent with the previously disclosed reduction plan, and the total number of shares reduced does not exceed the number of shares reduced disclosed in the reduction plan.
2. Mr. Wang Jianfei, the director of the company, promises that this reduction is consistent with the previous commitments made in the prospectus and other documents or announcements, and there is no violation of relevant commitments.
3. Mr. Wang Jianfei, the director of the company, strictly abides by the securities law of the people’s Republic of China, the stock listing rules of Shenzhen Stock Exchange and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board The detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of Listed Companies in Shenzhen Stock Exchange and other relevant laws, regulations, rules and business rules.
4. This reduction will not have a significant impact on the corporate governance structure, equity structure and sustainable operation.
3、 Documents for future reference
Notification letter of completion of share reduction plan issued by Mr. Wang Jianfei
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Board of directors
February 17, 2022
